Executive Summary
Cannabis Suisse Corp (CSUI) reported a flat revenue profile for QQ2 2025, with quarterly revenue of $7,500 and a minimal gross profit of $144 (gross margin 1.92%). The quarter’s profitability was dominated by a substantial GAAP operating expense load of $91,392, yielding an operating loss of $91,248 and an EBITDA of −$91,248 (EBITDA margin −12.17%). Net income of $5,062 appears to reflect a non-operating income item of $96,310, which temporarily conceals the deteriorating core earnings profile. On a cash-flow basis, operating cash flow was negative at $(19,142), and free cash flow was also $(19,142), with the cash balance ending at $4,100 versus $25,742 at the start of the period, underscoring a liquidity constraint.
Key Performance Indicators
QoQ: -21.93% | YoY:-79.97%
QoQ: 100.95% | YoY:109.24%
QoQ: 101.32% | YoY:108.33%
Key Insights
Revenue and profitability: Revenue $7,500; YoY 0%, QoQ 0%; Gross profit $144; Gross margin 1.92%; EBITDA $(91,248); EBIT $(91,248); Operating loss margin −12.17%. Net income $5,062; Net margin 6.75%; EPS $0.0001. Cash flow: Operating cash flow $(19,142); Free cash flow $(19,142). Balance sheet health: Total assets $751,847; Total liabilities $2,627,701; Shareholders’ equity $(1,875,854) (negative). Liquidity: Current ratio 0.485; Quick ratio 0.485; Cash ratio 0.0147. Leverage and coverage: T...
Financial Highlights
Revenue and profitability: Revenue $7,500; YoY 0%, QoQ 0%; Gross profit $144; Gross margin 1.92%; EBITDA $(91,248); EBIT $(91,248); Operating loss margin −12.17%. Net income $5,062; Net margin 6.75%; EPS $0.0001. Cash flow: Operating cash flow $(19,142); Free cash flow $(19,142). Balance sheet health: Total assets $751,847; Total liabilities $2,627,701; Shareholders’ equity $(1,875,854) (negative). Liquidity: Current ratio 0.485; Quick ratio 0.485; Cash ratio 0.0147. Leverage and coverage: Total debt $236,669; Net debt $232,569; Retained earnings $(3,130,928). Valuation/market posture: Price-to-sales ~179.06x (extremely elevated given tiny revenue base); Price-to-book negative; Enterprise value multiple negative. Four-quarter trend suggests flat top-line but persistent non-cash/non-operational distortions in profitability.
Income Statement
| Metric |
Value |
YoY Change |
QoQ Change |
| Revenue |
7.50K |
0.00% |
0.00% |
| Gross Profit |
144.00 |
-77.00% |
0.00% |
| Operating Income |
-91.25K |
-79.97% |
-21.93% |
| Net Income |
5.06K |
109.24% |
100.95% |
| EPS |
0.00 |
108.33% |
101.32% |
Key Financial Ratios
operatingProfitMargin
-1217%
operatingCashFlowPerShare
$-0
Management Commentary
No earnings-transcript data was provided in the supplied materials. Consequently, there are no management quotes or themes to quote or contextualize in this section. If transcripts are supplied, we will extract quotes by themes (strategy, operations, market conditions) and provide context for each.
Forward Guidance
No formal management guidance is included in the provided data. Consequently, forward-looking commentary is not possible from the supplied material. In a hypothetical scenario, investors should monitor: (1) any capital-raising actions or debt restructurings to stabilize liquidity, (2) progressive margin improvement through cost-control initiatives or product mix optimization, (3) potential asset sales or strategic partnerships leveraging Swiss4Life distribution channels, and (4) regulatory developments affecting CBD and OTC product categories. The achievability of any targets hinges on access to capital and successful execution of cost reductions and top-line growth.